Clinical trial
Comparison of Pilocarpine, Brimonidine, Oxymetazoline, Hialuronic Acid, Bromfenac Ophthalmic Compound With Pilocarpine and Brimonidine to Improve Uncorrected Visual Acuity in Healthy Presbyopic Individuals
NCT05001243 is registered in ClinicalTrials.gov with Optall Vision as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Comparison of Pilocarpine, Brimonidine, Oxymetazoline, Hialuronic Acid, Bromfenac Ophthalmic Compound With Pilocarpine and Brimonidine to Improve Uncorrected Visual Acuity in Healthy Presbyopic Individuals
- Lead sponsor
- Optall Vision
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- August 10, 2021
- Completion date
- September 10, 2021
- Enrollment
- 11 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.